US Senator investigates GSK for pulling children's asthma inhaler

U.S. Senator Maggie Hassan has launched an investigation into GlaxoSmithKline's (GSK) decision to discontinue its Flovent HFA asthma inhaler, effective January 2024, alleging the move has led to increased hospitalizations, deaths, and reduced access for low-income patients. Hassan claims GSK evaded an estimated $367 million in Medicaid rebates, costing the program over $550 million, by replacing Flovent with a higher-cost authorized generic. The probe demands detailed financial and health impact data, with the Senator calling for the inhaler's reinstatement amidst broader scrutiny over pharmaceutical pricing and patient affordability.

Analysis

GlaxoSmithKline (GSK) is facing a new U.S. Senate investigation, led by a key Democrat on the Finance Committee’s Health Care Subcommittee, creating significant regulatory and reputational headwinds. The probe centers on the company's January 2024 discontinuation of its Flovent HFA asthma inhaler and its replacement with a higher-priced authorized generic. The core allegation is that this was a strategic move to evade Medicaid rebate obligations, with a Johns Hopkins analysis cited by the Senator suggesting it saved GSK $367 million while costing the federal program over $550 million. The investigation carries material risk, as it demands internal documents on pricing and regulatory communications, with a deadline of July 18. While GSK has previously stated its distributor controls generic pricing and has announced a future $35 per month out-of-pocket cap for its asthma drugs starting in 2025, this action is framed as a reaction to broader industry pressure rather than a proactive solution to the current issue. The reported price spike for patients, from as low as $10 for Flovent to $150 for the generic, alongside claims of increased hospitalizations, amplifies the negative sentiment and potential for financial penalties or forced market actions.

Key Decisions for Investors

• Investors should closely monitor the Senate investigation's progress, particularly any disclosures following the July 18 document deadline, as this could reveal the extent of GSK's legal and financial exposure.
• The direct financial risk includes potential fines or mandated rebate payments that could exceed the alleged $367 million in savings, directly impacting future earnings and profitability.
• Evaluate the significant ESG and reputational risk, as allegations of prioritizing profits over child health could trigger divestment from socially conscious funds and erode long-term brand value.
• Consider this a potential bellwether for increased scrutiny on pharmaceutical pricing strategies across the industry, particularly the practice of switching from branded drugs to higher-cost authorized generics to circumvent rebates.